Strategies for clinical dose optimization of T cell-engaging therapies in oncology
ABSTRACTInnovative approaches in the design of T cell-engaging (TCE) molecules are ushering in a new wave of promising immunotherapies for the treatment of cancer. Their mechanism of action, which generates an in trans interaction to create a synthetic immune synapse, leads to complex and interconne...
Main Authors: | Kathryn Ball, Simon J Dovedi, Pavan Vajjah, Alex Phipps |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2181016 |
Similar Items
-
Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions
by: Yu Tang, et al.
Published: (2021-03-01) -
Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager
by: Samira Anbari, et al.
Published: (2023-06-01) -
Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors
by: Vladimir Voynov, et al.
Published: (2020-11-01) -
Translational PK/PD for the Development of Novel Antibiotics—A Drug Developer’s Perspective
by: Caterina Bissantz, et al.
Published: (2024-01-01) -
A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov
by: Jing Yang, et al.
Published: (2023-08-01)